

# ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC) Triple Negative Breast Cancer Colorectal Cancer (CRC) Renal Cell Cancer (RCC) Bladder Cancer Malignant Melanoma Melanoma Head and Neck Cancer

## A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

**Trial Status**  
Active, not recruiting

**Trial Runs In**  
8 Countries

**Trial Identifier**  
NCT03289962 2017-001475-23  
GO39733

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody).

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

---

**NCT03289962 2017-001475-23 GO39733**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥ 18 Years

**Healthy Volunteers**  
No

---